



an Open Access Journal by MDPI

Advances in Therapeutic Strategies and Precision Medicine in Solid Tumors and Metastasis

Guest Editors:

Dr. Silvia Di Agostino

Oncogenomic and Epigenetic Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Regina Elena National Cancer Institute, 00144 Rome, Italy

Dr. Giulia Fontemaggi

Regina Elena National Cancer Institute (IRCCS), Rome, Italy

Deadline for manuscript submissions:

closed (31 March 2024)

Message from the Guest Editors

This Special Issue of Biomedicines is dedicated to the most novel therapeutic strategies for the treatment of solid tumors.

Understanding molecular cancer pathogenesis has allowed scientists to develop increasingly effective treatment strategies. For some tumors, the use of personalized medicine throughout treatment with monoclonal antibodies, immunotherapy, and epigenetic drugs has already become a reality. In the future, the main objective will be to extend the possible molecular targets to make even tumors with a high incidence of metastasis and mortality more approachable with individualized anticancer therapies.

With this ambitious goal, we aim to collect in this Special Issue original research articles and reviews highlighting recent breakthroughs in personalized medicine and novel hypothetical targetable molecular mechanisms in the field of cancer. We welcome contributions assessing topics with robust molecular rationale in precision molecular therapy, nanodrug and molecule delivery, non-coding RNA-based therapeutics, as well as novel biomarkers useful in early diagnosis and prognosis.



mdpi.com/si/153907

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)